This is a news story, published by ScienceDaily, that relates primarily to Salk Institute news.
For more biology news, you can click here:
more biology newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
ARID1A mutation cancer patients. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest ARID1A gene mutations news, functional ARID1A tumors news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cancer immunotherapyScienceDaily
•78% Informative
Salk Institute researchers uncover why patients with ARID1A mutations are more likely to respond to cancer immunotherapy.
The findings could help improve cancer care and drug development for many cancer types, including endometrial, ovarian, colon, gastric, liver, and pancreatic cancers.
Researchers suggest this mutation could be used as a biomarker to better select patients for specific immunotherapies.
The findings are a major step in personalizing cancer treatment and inspiring novel therapies that target and inhibit ARID1A and its protein complex.
The Salk team hopes its findings can improve patient outcomes across the many cancer types associated with mutations.
The work was supported by the National Institutes of Health , Howard Hughes Medical Institute , Cancer Research Institute , Pew-Stewart Scholars for Cancer Research, American Cancer Society .
VR Score
88
Informative language
94
Neutral language
45
Article tone
formal
Language
English
Language complexity
66
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links